Myriad Genetics, Inc.'s MYGN MyRisk Hereditary Cancer Test with RiskScore study has been named as one of its top 10 significant advances in genomic medicine by the American Journal of Human Genetics. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute.
The all-in-one MyRisk with RiskScore test evaluates 48 genes associated with hereditary cancer risk to identify genetic changes associated with increased risk for 11 different cancers. According to the company, the latest development underscores the clinical significance of the validation research from the study and the predictive accuracy of RiskScore.
MYGN Stock's Likely Trend Following the News
After the announcement yesterday, Myriad Genetic shares edged up 0.8% in the after-hours trading. With MyRisk expected to continue its strong growth from expanded guidelines and acceleration of EMR integrations, we expect the latest news to positively boost the market sentiment toward MYGN stock.
Myriad Genetics has a market capitalization of $1.21 billion. The Zacks Consensus Estimate projects the company's 2024 earnings to increase by 144.4%. It delivered an average earnings beat of 247.73% in the trailing four quarters.
More on MYGN's RiskScore Study
The study by Mabey et al., "Validation of a clinical breast cancer risk assessment tool combining a polygenic score for all ancestries with traditional risk factors," presented a longitudinal clinical validation of MyRisk with RiskScore using data from more than 130,000 women referred for hereditary cancer genetic testing. RiskScore integrates a polygenic risk score (PRS) for all ancestries with the widely used Tyrer-Cuzick model. The study demonstrated that Myriad's PRS is a more accurate predictor of breast cancer risk than Tyrer-Cuzick alone. RiskScore delivered two times the ability to predict breast cancer risk than the Tyrer-Cuzick model.
Image Source: Zacks Investment Research
Myriad Genetics was one of the first commercial laboratories to market with a multi-ancestry breast cancer PRS, driven by its mission to advance health equity and deliver more inclusive genetic insights. Expressing gratitude for the recognition, the Chief Scientific Officer at MYGN stated that the selection of their paper as a major advance will continue to drive the adoption of RiskScore by providers and guideline societies.
Industry Prospects Favoring MYGN
Per a research report, the global hereditary cancer testing market was valued at $3.5 billion in 2021 and is expected to grow at a compound annual rate of 11.6% through 2031. The increasing geriatric population, a surge in the incidence of cancer worldwide and an increase in the government expenditure on healthcare are some of the main factors fueling the market's growth.
Other Developments in Myriad Genetics
Earlier this month, the company announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network ("NCCN") as an 'Advanced Tool' in the fight against prostate cancer. For many years, Prolaris has been included in NCCN guidelines with a category 2A level of evidence, which indicates that inclusion has support from at least 85% of members on the NCCN prostate panel.
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Penumbra PEN, Haemonetics HAE and Phibro Animal Health PAHC, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Penumbra shares have dropped 5.8% in the past year. Estimates for the company's 2024 earnings per share have increased 2 cents to $2.81 in the past 30 days. PEN's earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 10.54%. In the last reported quarter, it posted an earnings surprise of 23.19%.
Estimates for Haemonetics' fiscal 2025 earnings per share have remained constant at $4.59 in the past 30 days. Shares of the company have dropped 10.1% in the past year against the industry's growth of 9.8%. HAE's earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%. In the last reported quarter, it delivered an earnings surprise of 2.75%.
Estimates for Phibro Animal Health's fiscal 2025 earnings per share have increased 1.9% to $1.62 in the past 30 days. Shares of the company have surged 91.5% in the past year compared with the industry's 9.8% rise. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 25.47%. In the last reported quarter, it delivered an earnings surprise of 52.17%.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
Myriad Genetics, Inc. (MYGN) : Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.